Live-cell imaging enables acquisition of phase contrast images and provides an ideal platform to study multi-faceted biological paradigms in drug discovery. This is vital to our understanding of human diseases and treatment strategies. The movement of these models towards increasingly complex physiologically relevant ones, including patient-derived cells and induced pluripotent stem cells (iPSCs), has concurrently driven the need for label-free methods that are non-perturbing to deliver deeper biological insights.
The response of tumor cells, such as glioblastomas, to cytotoxic chemotherapeutic compounds is a complex and dynamic process that is crucial to understand in neurooncology research. Using pre-trained neural networks to accurately segment individual cells and classify them as live or dead is a powerful, robust approach for assessing cytotoxicity in glial cell types.
Examine the dynamic changes in cell morphology which occur when cells undergo ferroptosis and investigate label-free and fluorescence-based methods of kinetic quantification.
Phenotypic screening is a vital tool in drug discovery, enabling scientists to rapidly identify potential drugs early in the discovery pipeline. Kinetic information gained by repeated image acquisition within a physiologically relevant environment provides insight into the dynamic changes which are often overlooked using end-point analysis alone.
Webinar Date/Time: Tue, Jun 11, 2024 10:00 AM EDT
The evolution of regulatory guidelines for biosimilars alongside improvements in knowledge and understanding provide a platform for growth in the industry. Technology to support their rapid growth must simplify and streamline processes during drug development.
Webinar Date/Time: Wed, Jul 19, 2023 11:00 AM EDT
BridgeBio Pharma, Inc., and REGENXBIO Inc. take a novel approach to AAV capsid titer quantification by using Octet® AAVX Biosensors to generate viral titer data.
The rapid development of gene therapies and high demand for therapeutic proteins pose considerable challenges for biomanufacturing. Complex production processes, product changeover, managing supply chains, and staying ahead of the curve, to name just a few. To accelerate commercialization of biotherapeutics, organizations need to optimize processes by integrating advanced analytical tools that maximize quality, safety, and efficacy. The solution could be a comprehensive approach for screening and characterizing molecular interactions such as protein-protein or protein-drug interactions. It enables a huge variety of applications performed at various stages of biologics development — from early selection to validation to manufacturing. Based on Bio-Layer Interferometry (BLI), it enables real-time, label-free analysis for the determination of kinetics, affinity, and antibody/protein quantitation. Download this eBook to learn how the Octet® BLI platform can streamline workflows, reduce time-to-results, and costs saving on broad range of analytical applications in bioprocessing.
Webinar Date/Time: Wednesday, March 29th 2023 7am PDT | 10am EST | 4pm CEST